Craneware Cuts Forecast to $185M After Cyberattack
Craneware Cuts Forecast to $185M After Cyberattack
Anonymous
Key Points
1
Craneware converted 98% of adjusted EBITDA into cash during FY26, underscoring its strong cash-generation performance despite flat revenue.
2
Net revenue retention fell to 100% from 107% as expansion sales weakened, indicating that existing customers were spending no more overall than in the prior year.
3
The company completed a $25 million share buyback during FY26, while annual recurring revenue remained steady at $185 million.
4
Craneware expanded its Trisus platform by integrating datasets, rolling out AI-powered Trisus Assist and launching Trisus OneLink – Medication to address changing 340B and pharmacy-reimbursement requirements.
5
The company said the July cyber incident affected a significant volume of customer and partner records, although customer services and core operations were not disrupted and an independent investigation found its systems secure.
Craneware, a Scottish healthcare software firm, slashed its FY27 revenue forecast to $185 million after a July cyberattack. Investing.com reported the cut came despite solid FY26 results: revenue held steady at $206 million, profit before tax rose 7% to $25.8 million, and cash generation remained strong. The company maintained its 32-pence dividend but warned that remediation costs and potential customer engagement damage from the breach created too much uncertainty to project higher growth.
Cyberattack Threatens Growth Despite Stable Operations
In July, Craneware suffered a cyberattack that exposed a significant volume of customer and partner records. Herald Scotland confirmed that customer services and core operations were not disrupted. An independent investigation found systems remained secure. Yet the incident created enough uncertainty that management reset FY27 expectations downward, citing unknown remediation costs and potential impact on how customers engage with the platform.
Strong Cash Flow But Weak Expansion Sales Drag Revenue
Craneware converted 98% of adjusted EBITDA into cash during FY26, showing robust cash-generation power. Seeking Alpha highlighted that adjusted EBITDA grew to $67.1 million. However, net revenue retention fell to 100% from 107%, meaning existing customers spent no more overall than the prior year. Expansion sales weakened significantly, signaling reduced customer appetite to buy additional products.
Daily Business reported that shares crashed over 25% after the company announced the revenue reset. The 340B drug-discount program disrupted U.S. healthcare purchasing patterns, forcing pharmaceutical companies to compete harder on price—a headwind Craneware could not overcome despite strong cash output.
New Products and Cost Controls Position FY28 Recovery
Craneware launched three new products to address market shifts: AI-powered Trisus Assist, Trisus OneLink for pharmacy reimbursement, and expanded datasets within its Trisus platform. Sharecast noted the company completed a $25 million share buyback in FY26 while annual recurring revenue stayed steady at $185 million. Management began a cost review to protect margins as these new offerings ramp up.
The company expects improving 340B conditions and new product adoption to fuel a return to growth in FY28. However, Investing.com confirmed those benefits are not included in the current $185 million FY27 forecast—a deliberately conservative stance reflecting the uncertainty from the cyberattack and ongoing market pressures.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
20
Reach
34
A
AnonymousAuthor
